Diagnosis of Bone Metastasis in Men with Prostate Cancer by Measurement of Serum ICTP in Combination with Alkali Phosphatase and Prostate-specific Antigen

Clinical Oncology

Volumn 18, Issue 6, 2006, Pages 480-484

  Kataoka, A ^a   Yuasa, T ^a,b   Kageyama, S ^a   Tsuchiya, N ^b   Habuchi, T ^b   Iwaki, H ^a   Narita, M ^a   Okada, Y ^a   Yoshiki, T ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone metastasis; carboxy terminal telopeptide of type I collagen (ICTP); metabolic bone marker; prostate cancer; tumor marker

Indexed keywords

ALKALINE PHOSPHATASE; ANTIANDROGEN; CARBOXY TERMINAL TELOPEPTIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE SEVERITY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANDROGEN ANTAGONISTS; BIOLOGICAL MARKERS; BONE NEOPLASMS; COLLAGEN TYPE I; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 33745379989     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2006.02.010     Document Type: Article

References (18)

1. Jemal A., Tiwari R.C., Murray T., et al. American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
2. Nakata S., Takahashi H., Ohtake N., Takei T., and Yamanaka H. Trends and characteristics in prostate cancer mortality in Japan. Int J Urol 7 (2000) 254-257
3. Schroder F.H. Hormonal therapy of prostate cancer. In: Walsh P.C., Retik A.B., Vaughan Jr. E.D., and Wein A.J. (Eds). Campbell's urology. 8th edn (2002), Saunders, New York 3182-3208
4. Johansson J.E., Andren O., Andersson S.O., et al. Natural history of early, localized prostate cancer. JAMA 291 (2004) 2713-2719
5. Kylmala T., Tammela T.L., Risteli L., Risteli J., Kontturi M., and Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 71 (1995) 1061-1064
6. Yoshida K., Sumi S., Arai K., et al. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma. Cancer 80 (1997) 1760-1767
7. Maeda H., Koizumi M., Yoshimura K., Yamauchi T., Kawai T., and Ogata E. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol 157 (1997) 539-543
8. Noguchi M., and Noda S. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol 166 (2001) 1106-1110
9. Noguchi M., Yahara J., and Noda S. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 61 (2003) 993-998
10. Melkko J., Niemi S., Risteli L., and Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 36 (1990) 1328-1332
11. Risteli J., Elomaa I., Niemi S., Novamo A., and Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39 (1993) 635-640
12. Soloway M.S., Hardeman S.W., Hickey D., et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61 (1988) 195-202
13. Green J.R. Antitumor effects of bisphosphonates. Cancer 97 (2003) 840-847
14. Saad F., Gleason D.M., Murray R., et al. Zoledronic Acid Prostate Cancer Study Group: long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879-882
15. Nogawa M., Yuasa T., Kimura S., et al. Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. Oncol Res 15 (2005) 1-9
16. Nogawa M., Yuasa T., Kimura S., et al. Monitoring luciferase-labeled cancer cell growth and metastasis in in vivo models. Cancer Lett 217 (2005) 243-253
17. Yuasa T., Nogawa M., Kimura S., et al. A third generation bisphosphonate, minodronic acid (YM529), augments the interferon α/β-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo. Clin Cancer Res 11 (2005) 853-859
18. Kylmala T., Tammela T., Risteli L., Risteli J., Taube T., and Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer 29 (1993) 821-825